Industry Wants Congress To Renew R&D Tax Credit This Year
This article was originally published in The Gray Sheet
Executive Summary
Renewal of the federal research and development tax credit has emerged as a top priority for the device industry during Congress' upcoming lame-duck session
You may also be interested in...
Last-Minute Legislative Package Includes R&D Credit, Medicare Fixes
Congress was poised late last week to pass a legislative package extending a number of tax, trade and health provisions set to expire by year-end, but the bill fails to address some specific device industry priorities
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.